Objective: Trans-catheter aortic valve implantation is an alternative treatment option for patients facing high risk for aortic valve replacement. Currently, the results of trans-apical trans-catheter procedures performed outside controlled trials are unknown. Methods: The Edwards SAPIEN TM Aortic Bioprosthesis European Outcome (SOURCE) Registry collects data of patients treated at European centres during the first year following commercialisation of the Edwards SAPIEN TM bioprosthesis. Only data from centres that could provide 100% of their consecutively treated patients (n = 32) were included in the study population. This article provides the 30-day outcome data involving the trans-apical patients, including univariate and multivariate risk analyses for postoperative 30-day mortality. Results: The interim results are based on a total number of 575 procedures performed between January 2008 and 31 January 2009. Mean age at implant was 80.7 years, and patients had a mean logistic EuroSCORE of 29.1%. Baseline characteristics included coronary artery disease 56%, prior coronary intervention 27.1%, prior coronary bypass grafting 26.9%, concomitant mitral valve disease 32.8%, porcelain aorta 11.5%, peripheral vascular disease 27.5%, prior stroke 6.3% and pulmonary disease 29.4%. Successful valve deployment was observed in 92.7% with a 3.5% conversion rate to open surgery, incidence of coronary obstruction of 0.7% and valve embolisation of 0.5%. The incidence of aortic regurgitation in excess of 2+ was 2.3% immediately following the procedure. The incidence of major postoperative complications included bleeding requiring re-operation 2.1%, dialysis 7.1%, pacemaker implantation 7.3%, stroke 2.6%, major vascular complications 2.4% and myocardial infarction 0.7%. The total 30-day mortality was 10.3%. Logistic EuroSCORE !30% and missing ejection fraction were found to be the only independent predictors for 30-day mortality.
Introduction
Increased life expectancy has resulted in a growing elderly population and, consequently, an increase in the number of patients with aortic valve disease. Severe aortic stenosis (AS) represents the most common indication for aortic valve replacement (AVR) [1] . The main cause of acquired AS in Europe and the United States is senile degenerative calcification [1] . Once symptoms appear, the prognosis is very poor [1] . AVR is the gold standard treatment for AS with excellent survival; however, elderly patients and patients suffering from severe co-morbidities face higher operative risks [2] . This explains why these patients are often not referred or considered for surgery which results in approximately 67% of patients with severe AS being surgically treated [3] .
To mitigate surgical trauma and morbidities associated with AVR, minimised access AVR was developed, which reduced surgical trauma, but still required extracorporeal circulation with its associated complications [4] .
Subsequent rapid progression of trans-catheter therapeutics has led to trans-catheter aortic valve implantation (TAVI), which can be performed without a sternotomy on the beating heart [5] . Recently, the Edwards SAPIEN TM valve was approved for commercial use in the European Union; the transfemoral (TF) delivery was approved in November 2007 and trans-apical (TA) delivery in January 2008.
To assess the safety of this innovative technology, the Edwards SAPIEN TM Aortic Bioprosthesis European Outcome (SOURCE) Registry was created to obtain clinical data involving the commercially available Edwards SAPIEN TM valve, delivery devices and delivery procedure in patients with severe symptomatic AS. This article describes the early results of registry patients, who underwent trans-apical TAVI (TA-TAVI).
Materials and methods

Registry
A total of 34 centres participated in the initial commercial launch of the Edwards SAPIEN TM trans-catheter valve in Europe. A total of 1123 patients underwent attempted TAVI at these centres between November 2007 and 31 January 2009. To produce a scientifically robust data set, only centres that could provide data on 100% of their consecutively treated patients during this time were used for the present analysis. Two centres (with a total of 85 patients) were excluded due to their inability to obtain Ethics Committee approval, provide sufficient administrative support and/or supply data involving all consecutive patients. In the remaining 32 centres, 1038 patients were treated. This group is named COHORT 1 for future reference to these data and includes 575 patients who underwent TAVI using the TA approach.
Out of the 32 centres, 23 centres (72%) started their TAVI programme after the Registry was opened and a total of 324 TA patients (56%) were treated at these centres. In this article, we present the 30-day results involving TA-TAVI patients, including univariate and multivariate risk analyses of 30-day mortality.
Guidelines for commercial use of the Edwards SAPIEN TM valve
As outlined in the directions for use under CE mark restrictions, the SAPIEN TM valve can be used in patients with symptomatic AS (aortic valve area <0.8 cm 2 ) requiring AVR who face high risk for traditional AVR, or are 'non-operable' as determined by either (or both) the logistic EuroSCORE >20% or the STS risk score >10 [6] . In addition, treatment may be performed if two independent cardiac surgeons conclude that the patient has specific co-morbidities such as porcelain aorta, surgical access problems and severe respiratory disease, which are not adequately reflected in the surgical risk determined by the calculated logistic EuroSCORE. Contraindications for the TA approach include non-valvular, congenital or non-calcific acquired AS; intracardiac mass, thrombus or vegetation; untreated clinically significant coronary artery disease (CAD) requiring revascularisation; severe deformation of the chest; severe coagulation problems; active bacterial endocarditis or other active infections; myocardial infarction (MI) within the prior month; unstable angina during the index procedure; recent pulmonary emboli or cerebrovascular accident (CVA); inability to tolerate anticoagulation therapy; hypertrophic cardiomyopathy and severe ventricular dysfunction with ejection fraction <20%.
Procedures and devices
The Edwards SAPIEN TM valve (Edwards Lifesciences, Inc., Irvine, CA, USA) combines balloon-expandable stent and bioprosthetic valve technology. The bioprosthesis is comprised of a radio-opaque, stainless steel stent, an integrated unidirectional trileaflet tissue valve and polyethylene terephthalate fabric cuff. The valve tissue is fabricated from bovine pericardium preserved in glutaraldehyde. The Edwards SAPIEN TM trans-catheter heart valve is available in two sizes (23 mm and 26 mm). Prior to implantation, the bioprosthesis is mounted and crimped onto a balloon delivery catheter using a specially designed crimping device. For the TA approach, the bioprosthesis is inserted through the apex of the left ventricle and delivered to the site of the native stenotic aortic valve using the Ascendra TM delivery system [7] .
Training and proctoring
Each commercial site underwent a structured programme of training and proctorship. This consisted of teams comprising cardiac surgeons, cardiologists, nurses and technicians from the new institution visiting a training centre for didactic and simulator training followed by compulsory visits to experienced centres to observe at least one TF and one TA case. Finally, proctors attended at least the first two cases involving each approach at the new institution.
Definitions and data collection
Anonymised data are collected and used to generate the analyses for this registry. Patients were/will be assessed at discharge, 30 days and 12 months postimplantation. As expected from the criteria for inclusion into this registry, data submission was high with 100% procedural data and 98% of survival data available at the 30-day follow-up visit.
In the SOURCE registry, events and values collected are site-reported and there are no core laboratories. The principal investigators (OW, MRT) reviewed and adjudicated all clinical and adverse events reported to the Medidata RAVE electronic database. No functional assessment of the Edwards SAPIEN TM valve has been reviewed for this article. Measures of outcome in the SOURCE registry are death, acute procedural success (defined as successful deployment of the valve, retrieval of the catheter, no conversion to conventional surgery and patient exited the intervention room alive), stroke, vascular complications, permanent pacemaker insertion, renal dysfunction requiring dialysis, coronary complications and device embolisation.
Vascular complications were separated into major and minor complications. A major vascular complication is defined as limb-threatening ischaemia, vessel rupture requiring additional non-planned vascular surgery or additional interventional treatment and complications of the left ventricle.
Statistical analysis
Continuous variables are presented as mean AE standard deviation (SD) and were compared between groups using the two-sample t-test. Categorical variables are given as frequencies and percentages, and were compared using Fisher's exact test. All statistical analysis was performed using SAS, version 9.2 (SAS Institute Inc, Cary, NC, USA).
Thirty-day survival is based on days past the valve implant, without consideration of discharge from hospital. The percentage of patients censored prior to 30 days is less than 1%, and pure proportion and Kaplan-Meier estimates of 30-day survival differ by approximately 0.1%. For ease of presentation and computation, 30-day survivals were evaluated as pure proportions except where otherwise stated in the article text.
Missing baseline data are a potential issue in the risk analyses. The STS risk score was missing in over 40% of the patients, and this variable was not used in the risk analyses; use of the term EuroSCORE in this article refers to mean logistic EuroSCORE. For variables used in risk analyses, the proportion of missing baseline data was less than 2% with two notable exceptions: New York Heart Association (NYHA) classification was missing in 5.9% of the patients and ejection fraction in 17.4%. Univariate risk analyses were performed by Fisher's exact test for binary risk factors and by logistic regression for continuous risk factors; no imputation was made for missing data in the univariate analyses. For multivariable analyses, logistic regression was used, and missing baseline values were imputed to be the mean of observed values. Wald p values are presented for logistic regression analyses.
The missing data pattern for ejection fraction presented a special challenge, since missing ejection fraction was significantly correlated with 30-day mortality. Details are given in the section titled 'Results'.
Statement of responsibility
The principal investigators had full access to the reported data and take responsibility for the integrity of the data presented in the article. All authors have read and agreed to the article as written.
Results
Demographics and baseline data
Demographic and baseline characteristics are shown in Table 1 . Mean age at TA-TAVI was 80.7 years, and female patients (56%) were slightly more in number than males. A significant number of patients had concomitant mitral valve disease (32.8%) and pulmonary disease (29.4%). Main comorbidities were related to atherosclerosis. CAD was reported for 321 patients (56%) as evidenced by prior MI (18.3%), percutaneous coronary intervention (27.1%) and coronary artery bypass grafting (26.9%). A high incidence of renal dysfunction (32.9%), peripheral vascular disease (27.5%) and carotid artery disease >50% (17.1%) was observed. A total of 66 patients had porcelain aorta (11.5%), 55 patients (9.6%) experienced transient ischaemic attacks and 6.3% patients suffered from stroke prior to the Table 1 Demographic and baseline characteristics (N = 575).
Variable
Mean AE SD or % Missing % 
Operative data
Operative data are provided in Table 2 . Nineteen patients underwent Edwards SAPIEN TM valve-in-Edwards SAPIEN TM valve implantation, resulting in a total of 594 Edwards SAPIEN TM valves used in this cohort. Acute procedural success was observed in 92.7%. Malposition of the valve, that is, deployed slightly too high or too low causing either aortic regurgitation (AR) or coronary obstruction was observed in eight cases and all these instances required a valve-in-valve procedure. The indication for a valve-in-valve treatment in an additional 11 cases was a report of severe paravalvular leakage or AR. In 20 cases (3.5%), complications during TA-TAVI required conversion to open heart surgery. AR >grade 2+ was noted in 13 cases (2.3%) at the end of the procedure. Conversion to open heart surgery and postoperative AR >grade 2+ were significant risk factors for 30-day mortality. Coronary obstruction requiring intervention occurred in only four cases (0.7%). The overall incidence of valve embolisation was low (n = 3 or 0.5%). In two cases, the valve embolised into the ventricle and both procedures were converted to open heart surgery; one patient was alive at day 30, and the other patient died due to sepsis on day 19. In the third instance, the patient had severe central AR following valve deployment and a valve-in-valve implantation was attempted, which caused the first valve to migrate into the ascending aorta; the first valve was stented into the wall of the aorta and the patient is reportedly doing well.
Major complications
Major complications are shown in Table 3 . In general, 30-day mortality was 10.3% (59/575), and 16 of the 59 patients (27.1%) died within 72 h. The early deaths included seven patients with heart failure, including one patient with a preoperative ejection fraction of <15% and four accessrelated complications (one case each of aortic dissection, apical rupture, apical bleeding and left ventricular tear). In addition, one patient died due to each of the following complications: cardiac arrest due to temporary pacemaker failure; gastrointestinal complication; MI and multi-organ failure. In general, the majority of all deaths were caused by multi-organ and heart failure (28/59 or 47.5%). Five patients (8.5%) suffered a cardiac arrest on post-procedural days 1, 5, 6, 9 and 21, respectively. Twelve patients (2.1%) experienced early postoperative bleeding requiring re-operation. The incidence of permanent pacemaker implantation was 7.3%. The incidence of stroke was 2.6%. Renal failure requiring dialysis occurred in 7.1% of cases and showed a high risk for a fatal outcome with a 30-day mortality of 19.5% in these patients and a trend to predict 30-day mortality of 0.06. A total of 27 vascular complications were reported; 17 major vascular/access events and 10 minor vascular complications. The 17 major vascular/access complications involved 14 patients (2.4%) and consisted of aortic dissections (n = 5), aortic annular rupture (n = 1) and complications of the left ventricular apex (n = 11). Patients with major vascular/access complications showed a high mortality rate with 7/14 patients (50%) dying after surgery, which was significantly higher than the mortality rate observed in patients, who did not experience major vascular/access complications ( p < 0.001).
Postoperative length of stay in the intensive care unit (ICU) is only available for 84% of TA patients. The length of stay varied widely in these 482 patients across countries and regions with a median ICU stay of 2 days (range 0-89 days). The proportion of patients with an ICU stay of not more than 2 days was 55% (267/482).
Univariate analysis
Various baseline factors were considered to develop models for prediction of 30-day mortality (Table 4) . Three continuous risk factors (age, EuroSCORE and ejection fraction) were considered (Table 5 ). To more easily interpret the odds ratios, the parameters were divided by 10. This scaling does not impact the p values. Scaled logistic EuroSCORE ( p = 0.008), and scaled ejection fraction (0.009) are highly significant predictors of death. However, the ejection fraction is missing for more than 15% of the patients. As noted in Table 4 , a missing value for ejection fraction is in itself a highly significant predictor of 30-day mortality ( p = 0.019). As the missing pattern is informative for death, there is no simple way to impute values for the missing ejection fractions. Accordingly, the univariate p value for ejection fraction should be viewed judiciously. In an effort to better understand the missing ejection fractions, the 40 cases where the echocardiogram was read but the Table 4 . Because of interest in using logistic EuroSCORE as a predictor, binary variables were created with two different cut-offs. The statistically significant binary predictors of 30-day mortality are logistic EuroSCORE !30% ( p = 0.048), missing ejection fraction ( p = 0.019) and carotid artery stenosis ( p = 0.027). The carotid artery stenosis term is counterintuitive, with the death rate lower by a factor of almost 3 in patients who have carotid artery stenosis.
Multivariate analysis
The various baseline values were included in a multivariable logistic regression. Three specific challenges arose in the analysis:
Logistic EuroSCORE is important both as a continuous variable and with various cut-offs. As the continuous value showed a lower p value in the univariate analysis, only the continuous logistic EuroSCORE was used in the multivari- When ejection fraction is excluded, both forward variable selection and backward elimination resulted in the two-variable model presented in Table 6 . The cstatistic (area under the curve) is 0.655, and 0.611 for EuroSCORE alone (Fig. 1) . The two independent predictors for 30-day mortality were scaled logistic EuroSCORE ( p = 0.002) and carotid artery stenosis ( p = 0.015). If the significance criterion for entry into the model is relaxed to 0.10, the 'liver disease' term enters as well. In both cases, no new risk factors enter the multivariate model if the carotid artery stenosis term is excluded from the analysis.
In the second analysis, the dummy variable for the missing ejection fraction is also significant, but ejection fraction itself is not; the c-statistic increases to 0.674. Both models are presented in Table 6 . The authors prefer the first model because the clinical interpretation for missing ejection fraction is speculative; some discussion on this topic is provided below.
Discussion
AVR is a highly effective and safe surgical treatment for AS with an average reported operative mortality in the STS database of 3.4% [8] . However, age and co-morbidities such as concomitant CAD, repeat cardiac surgery, renal failure, respiratory disease and peripheral/cerebral vascular disease result in impaired outcomes [2, [9] [10] [11] .
In the past, there were no long-lasting treatment alternatives for high-risk patients suffering from symptomatic AS. Interventional techniques, such as balloon aortic valvuloplasty (BAV), have been attempted to treat high-risk patients with AS. BAV does result in a small increase in aortic valve area. Since re-stenosis is frequent, BAV provides only temporary improvement of valvular function and relief of symptoms. BAV has also high rates of procedure-related morbidity and mortality, with reported procedural mortality of 3% and 30-day mortality of 14% [12] .
TAVI is a new surgical/interventional technique introduced by Cribier et al. in 2002 , where implantation of a bioprosthesis is feasible without sternotomy and is performed on the beating heart. At that time, Cribier used the complex antegrade trans-septal approach [5] . Since then, the retrograde TF-TAVI has been developed, which still has limitations when exclusionary vascular access-related conditions, such as significant atheroma, severe tortuosities and small diameters of femoro-iliac vessels or the aorta, are present. The potential advantage of the TA approach is that it has no limitations with regard to vascular access.
To test TAVI, numerous feasibility studies were performed. Subsequent controlled investigations involving over 400 patients implanted with the Edwards SAPIEN TM bioprosthesis in both delivery approaches resulted in the CE mark certification for its commercial use. The European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC) have deemed TAVI a promising technique, which may offer an alternative to conventional AVR for high-risk patients with AS. However, at present it is seen to be appropriate only in patients facing high surgical risk or who are unsuitable for surgery; uncontrolled diffusion should be avoided [6] .
Prediction of operative risk for patients undergoing AVR, however, is a challenging task. In Europe, the EuroSCORE was established to calculate prospective mortality in patients undergoing cardiac surgery [13] and it was and still is used to identify high-risk patients awaiting AVR. However, it is important to note that when the EuroSCORE was developed in 2003, it was mainly based on data generated from coronary artery bypass grafting. Recent publications demonstrate that the EuroSCORE overestimates the mortality in patients undergoing AVR, particularly in patients with high logistic EuroSCOREs [7, 12, 14, 15] . Note: EuroSCORE has been divided by 10 in order to aid in interpreting the odds ratio. This scaling does not otherwise impact the analysis. It is, however, interesting that the co-morbidities of formerly operated octogenarians are fewer than in younger patients, making it likely that there has been a selection bias in the past when excluding very sick octogenarians from AVR treatment [16] . This may also explain why new reports, which compare the risk profile of former octogenarian cohorts with present TAVI cohorts, found significantly higher logistic EuroSCOREs in the TAVI group, that is, 16.3% versus 21.5%, respectively [17] .
The SOURCE Registry was established to assess the results of TAVI outside controlled trials and in an attempt to identify preoperative risk factors that predict postoperative mortality. Initial commercial rollout was limited to 34 European centres, and 32 of these centres provided scientifically sound data. It is important to note, that overall, 23 sites (72%) had no prior experience with the Edwards SAPIEN TM valve and that a total of 324 TA patients (56%) were treated in these centres. Demographic data of the TA-TAVI patients with a mean EuroSCORE of 29.1% indicate that implantations were still performed according to the CE mark certification in a group of patients facing high risk for AVR.
Various centres have published their learning curve with TA-TAVI earlier. Webb et al. [18] reported an overall 30-day mortality rate of 18.2% in 55 TA-TAVI patients. This rate was initially 25% and decreased to 11.1% in the second half of the TA-TAVI cohort. Walther et al. observed a mortality of 13.6% in their early series and recently showed 30-day mortality results of 8% [19] . Although comparison with former reports of pioneering series are difficult, early results in the SOURCE registry with procedural success of 92.7% and 30-day mortality of 10.3% indicate that the way the TA approach has been introduced since commercialisation is safe and the learning curve has been minimised.
The trend for post-procedure renal failure is strongly significant for mortality ( p = 0.06). Naturally, renal failure is multifactorial and is also associated with the atherosclerotic risk profile of TA-TAVI patients. However, postoperative complications such as major vascular/access problems, the postoperative presence of AR >2+ and conversion to conventional AVR are procedural complications, which may be preventable with improved intra-operative techniques and smaller future devices. As all of them were significant predictors for 30-day mortality ( p 0.001, p 0.001 and p 0.0001, respectively), it can be speculated that this could significantly improve 30-day mortality in the future.
The univariate analysis was based on more than 30 risk factors (Tables 4 and 5 ). It showed that the strongest predictor for 30-day mortality is the continuous logistic EuroSCORE ( p = 0.008) and scaled ejection fraction ( p = 0.009). This is not unexpected, as the incidence of acute complications during the procedure is quite low and therefore, postoperative mortality is mainly a result of cardiac co-morbidity, which is very well reflected by the EuroSCORE. However, baseline ejection fraction missing is also a significant predictor for mortality (0.019), and although it makes clinical sense that a lower left ventricular ejection fraction increases the risk of 30-day mortality, it is more difficult to understand why a missing left ventricular ejection fraction would be significant for mortality. One explanation could be that these patients were considered for TA-TAVI based on their logistic EuroSCORE of >20%. The EuroSCORE treats a missing left ventricular function value the same as left ventricular function 'good'. Even for patients with missing left ventricular ejection fraction, the mean logistic EuroSCORE was still 29.2%, which likely means that if the ejection fraction would have been added, the resulting logistic EuroSCORE and predicted risk for these patients would have been even higher.
It was even more surprising that a carotid artery stenosis of >50% was significant for mortality in a counterintuitive direction, that is, it predicted better 30-day survival ( p = 0.027). This may be only a statistical phenomenon; however, we found that the risk of stroke for patients with significant carotid artery disease in the TA-TAVI group was 1.0% (1/98) and thus not significantly different to patients without carotid artery disease (2.9%, 14/475, p = ns). An explanation may be that in conventional AVR, the increased stroke risk in patients with carotid artery disease is a result of malperfusion (low blood pressure while the patient is on cardiopulmonary bypass) and embolic risk (embolism of air or debris from the valve or aorta). In TAVI, however, malperfusion plays less of a role, because rapid pacing during implantation is limited to short sequences. Further, air embolism is less of a problem compared with AVR. However, the risk of embolism of debris still exists, but one could hypothesise that the obstruction of the carotid artery reduces the embolic risk due to decreased inflow. This would explain why the incidence of stroke is not increased in this particular group; however, it still does not explain why these patients have an improved survival.
For the multivariate analysis, missing ejection fraction was not considered, due to the informative pattern of missing data. However, since ejection fraction is a component of logistic EuroSCORE it might well have not remained in a multivariable analysis in any case. In the TA only analysis, the independent predictors are logistic EuroSCORE and carotid artery stenosis. In an additional analysis of the SOURCE registry, considering all patients (TA and TF), and including a term for implant approach, the logistic EuroSCORE is again the best predictor of 30-day mortality ( p < 0.0001).
The fit of the prediction model leaves much to be desired. The c-statistics (area under the receiver operating characteristic (ROC) curve (Fig. 1) ) is 0.611 for the model with EuroSCORE alone, 0.655 when carotid artery stenosis is added and 0.659 if the liver disease term is also added. Other linear logistic models have not yielded notably better results for prediction in the TA approach; further investigation should include interaction and non-linear terms.
With larger patient numbers, it will also be easier to develop a particular risk scoring for TAVI. It also may be helpful for the future to implement additional risk scores for frailty of the patients, which could be developed in cooperation with geriatrists.
Limitations of the SOURCE Registry
The SOURCE Registry is a clinical registry and contains limited functional assessment of the Edwards SAPIEN TM valve. In addition, all adverse events were self-reported by the participating centres; no adjudication of adverse events via source documentation was assessed. However, review and adjudication of all serious adverse events and adverse events in the electronic database was performed by the principal investigators.
Conclusion
These results demonstrate that despite TA-TAVI being a new and complex surgical technique, the learning curve can be minimised with adequate training and multidisciplinary patient selection. However, given the fact that intraoperative complications, which result in conversion to open heart surgery, AR >grade 2+ and valve-in-valve treatment, are significant risk factors for 30-day mortality, even further improvement can be expected in the future.
Although the logistic EuroSCORE does not predict actual risk, it is the strongest predictor for 30-day mortality available at present. Larger patient cohorts will make it more likely that additional predictors for early survival will be identified in the future. option comes first versus those centres where the transfemoral approach is considered first choice?
Dr Wendler: We haven't looked into that, and the reason why is that it is sometimes quite difficult to understand how many centres there are where trans-apical comes first. Complete results comparing transfemoral and transapical have been presented before, and it is very obvious that the two groups, the trans-apical group and the transfemoral group, are completely different groups in terms of demographic data. The trans-apical group is much sicker and in all variables for comorbidities have a significant difference to the transfemoral group.
It would be interesting, for example, to see if in the centres where transapical comes first the results are better, but, unfortunately, we don't have this information for the analysis.
Dr J. Gerhardus (Karlsruhe, Germany): You showed us as a preoperative risk factor, implanted pacemaker. Is there a reason why? Because we know we have AV blocks postoperatively, so it should be even better to have one maybe.
Dr Wendler: The point is if you want to count the pacemakers you have after surgery, you need to know how many pacemakers patients had already before surgery. That does not mean that they got the pacemaker because they underwent TAVI, but it means that these patients had pacemakers implanted for other reasons in the past, let's say AV block in the past or whatever it was. But it had nothing to do with the operation.
Dr J. Ennker (Lahr, Germany): The mortality of the patients converted to surgery increased five fold, 45%. What were the reasons? Could you identify patients who are at risk for conversion? Did this happen in the early phase of the experience or is it something you have to calculate always?
Dr Wendler: The problem was all the patients who were converted to conventional surgery were patients who suffered from intra-operative complications of the TAVI. These were usually complications like annular rupture or aortic dissection, embolisation of the valve, or anything like that. So that means you usually have a really serious problem. And that explains why these patients usually when you convert them were in a relatively disastrous condition and therefore I think the outcome is so inferior. We are not talking about patients who were identified as patients where TAVI was not feasible and therefore they were planned for conventional surgery. These were only patients who had an intra-operative complication and were converted because of that problem.
